Incyte (INCY) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45337C1027

Cancer, Lymphoma, Leukemia, Inflammation, Autoimmune

Incyte Corporation is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative treatments for various diseases. The company's primary areas of focus include hematology/oncology, inflammation, and autoimmunity.

Their portfolio of products includes JAKAFI, a treatment for myelofibrosis, polycythemia vera, and acute graft-versus-host disease. They also offer MONJUVI and MINJUVI for relapsed or refractory diffuse large B-cell lymphoma, and PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for treating various types of cancer. Additionally, they have ICLUSIG for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, and ZYNYZ for treating metastatic or recurrent locally advanced Merkel cell carcinoma.

Incyte Corporation also offers OPZELURA cream for treating atopic dermatitis. Their pipeline includes retifanlimab, which is in Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer. They are also developing axatilimab, an anti-CSF-1R monoclonal antibody, for treating chronic graft-versus-host disease.

The company has several other products in development, including INCA033989, INCB160058, INCB99280, and INCB99318, which target various types of cancer. They are also working on Ruxolitinib cream, Povorcitinib, and INCA034460. Incyte Corporation has partnerships with several companies, including Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited.

Incyte Corporation sells its products to a range of customers, including specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company has undergone significant changes since its inception, including a name change from Incyte Genomics Inc to Incyte Corporation in 2003. Today, Incyte Corporation is a leading biopharmaceutical company dedicated to improving patient outcomes through innovative treatments.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Incyte (INCY) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Incyte (INCY) - Stock Price & Dividends

INCY Stock Overview

Market Cap in USD 13,302m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1993-11-04

INCY Stock Ratings

Growth 5y -37.5
Fundamental 74.6
Dividend -
Rel. Performance vs Sector -0.39
Analysts 3.92/5
Fair Price Momentum 59.31 USD
Fair Price DCF 96.39 USD

INCY Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

INCY Growth Ratios

Growth 12m 1.23%
Growth Correlation 12m -32%
Growth Correlation 3m 46%
CAGR 5y -6.15%
CAGR/Mean DD 5y -0.22
Sharpe Ratio 12m -0.16
Alpha vs SP500 12m -17.51
Beta vs SP500 5y weekly 0.61
ValueRay RSI 91.16
Volatility GJR Garch 1y 24.71%
Price / SMA 50 12.33%
Price / SMA 200 9.17%
Current Volume 9700.7k
Average Volume 20d 5876.5k

External Links for INCY Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of INCY stocks?
As of June 22, 2024, the stock is trading at USD 63.22 with a total of 9,700,687 shares traded.
Over the past week, the price has changed by +1.79%, over one month by +10.14%, over three months by +9.53% and over the past year by +2.15%.
What are the forecast for INCY stock price target?
According to ValueRays Forecast Model, INCY Incyte will be worth about 65.5 in June 2025. The stock is currently trading at 63.22. This means that the stock has a potential upside of +3.56%.
Issuer Forecast Upside
Wallstreet Target Price 71.9 13.7
Analysts Target Price 82.1 29.9
ValueRay Target Price 65.5 3.56